Effect of Pamidronate on Bone Loss After Kidney Transplantation: A Randomized Trial

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 856-865

  Walsh, Stephen B ^a   Altmann, Paul ^b   Pattison, James ^c   Wilkie, Martin ^d   Yaqoob, Muhammad M ^e   Dudley, Christopher ^f   Cockwell, Paul ^g   Sweny, Paul ^a   Banks, Linda M ^h   Hall Craggs, Margaret ⁱ   Noonan, Kate ^e   Andrews, Christopher ^j   Cunningham, John ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^j Novartis Pharma UK Ltd   (United Kingdom)

more..

Author keywords

bisphosphonates; control trial; fracture; osteoporosis; pamidronate; Renal transplantation

Indexed keywords

CALCICHEW; CALCIUM; CALCIUM PLUS VITAMIN D3; COLECALCIFEROL; CYCLOSPORIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP FRACTURE; HUMAN; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PERIOPERATIVE PERIOD; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SPINE FRACTURE; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; POSTOPERATIVE COMPLICATIONS; RADIOIMMUNOASSAY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64749099481     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.036     Document Type: Article

References (30)

1. Cunningham J. Posttransplantation bone disease. Transplantation 79 (2005) 629-634
2. Stehman-Breen C.O., Sherrard D.J., Alem A.M., et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58 (2000) 2200-2205
3. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Use of oral corticosteroids and risk of fractures. June, 2000. J Bone Miner Res 20 (2005) 1487-1494
4. Wolpaw T., Deal C.L., Fleming-Brooks S., Bartucci M.R., Schulak J.A., and Hricik D.E. Factors influencing vertebral bone density after renal transplantation. Transplantation 58 (1994) 1186-1189
5. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 18 (2007) 223-234
6. Epstein S. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton. J Bone Miner Res 11 (1996) 1-7
7. Grotz W.H., Mundinger F.A., Gugel B., Exner V., Kirste G., and Schollmeyer P.J. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation 58 (1994) 912-915
8. Julian B.A., Laskow D.A., Dubovsky J., Dubovsky E.V., Curtis J.J., and Quarles L.D. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325 (1991) 544-550
9. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15 (2003) 454-457
10. Movsowitz C., Epstein S., Fallon M., Ismail F., and Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology 123 (1988) 2571-2577
11. Sass D.A., Bowman A.R., Yuan Z., Ma Y., Jee W.S., and Epstein S. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 21 (1997) 65-70
12. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 (1997) 382-387
13. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995) 1437-1443
14. Fan S.L., Almond M.K., Ball E., Evans K., and Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57 (2000) 684-690
15. Fan S.L., Kumar S., and Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 63 (2003) 2275-2279
16. Grotz W., Nagel C., Poeschel D., et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12 (2001) 1530-1537
17. Lee S., Glicklich D., and Coco M. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. Nephrol Dial Transplant 19 (2004) 2870-2873
18. Monier-Faugere M.C., Mawad H., Qi Q., Friedler R.M., and Malluche H.H. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11 (2000) 1093-1099
19. Briner V.A., Thiel G., Monier-Faugere M.C., et al. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 59 (1995) 1393-1400
20. Coco M., Glicklich D., Faugere M.C., et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14 (2003) 2669-2676
21. Weber T.J., and Quarles L.D. Preventing bone loss after renal transplantation with bisphosphonates: We can ... but should we?. Kidney Int 57 (2000) 735-737
22. Coen G., Ballanti P., Bonucci E., et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 13 (1998) 2294-2302
23. Almond M.K., Kwan J.T., Evans K., and Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66 (1994) 52-57
24. Palmer S., McGregor D.O., and Strippoli G. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev (Online) (2007) CD005015
25. Haas M., Leko-Mohr Z., Roschger P., et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63 (2003) 1130-1136
26. Kovac D., Lindic J., Kandus A., and Bren A.F. Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 70 (2000) 1542-1543
27. Fisher E.S., Baron J.A., Malenka D.J., Barrett J., and Bubolz T.A. Overcoming potential pitfalls in the use of Medicare data for epidemiologic research. Am J Public Health 80 (1990) 1487-1490
28. Genant H.K., Jergas M., Palermo L., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11 (1996) 984-996
29. Giannini S., D'Angelo A., Carraro G., et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16 (2001) 2111-2117
30. Grotz W.H., Rump L.C., Niessen A., et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66 (1998) 1004-1008